Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
LOS ANGELES, Aug. 21, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (Nasdaq:IPCI) for possible violations of federal securities laws between January 14, 2016 and July 26, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired IntelliPharmaCeutics shares during the Class Period should contact the firm prior to the September 29, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When this news reached the public, shares of IntelliPharmaCeutics lowered in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
